Howard Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Howard Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.77M	Sell	3,970 -5,304	-57%	-$2.47M	0.03%	133
2025 Q4	$4.2M	Buy	9,274 +360	+4%	+$155K	0.05%	109
2025 Q3	$3.49M	Sell	8,914 -4	-0%	-$1.67K	0.05%	118
2025 Q2	$3.97M	Buy	8,918 +2,282	+34%	+$1.05M	0.06%	105
2025 Q1	$3.22M	Sell	6,636 -1,021	-13%	-$476K	0.08%	102
2024 Q4	$3.08M	Buy	7,657 +224	+3%	+$104K	0.05%	111
2024 Q3	$3.46M	Buy	+7,433	New	+$3.57M	0.06%	102
2020 Q4	–	Sell	-1,859	Closed	-$506K	–	65
2020 Q3	$506K	Sell	1,859 -761	-29%	-$210K	0.12%	40
2020 Q2	$768K	Buy	+2,620	New	+$710K	0.22%	26
2020 Q1	–	Sell	-4,979	Closed	-$726K	–	48
2019 Q4	$726K	Buy	4,979 +3,472	+230%	+$703K	0.25%	17
2019 Q3	$255K	Buy	1,507 +5	+0.3%	+$885	0.11%	36
2019 Q2	$254K	Sell	1,502 -127	-8%	-$22.2K	0.11%	35
2019 Q1	$310K	Buy	+1,629	New	+$301K	0.16%	35

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Howard Capital Management's VRTX Position: Q1 2026 in Review

Howard Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 57% in Q1 2026, selling an estimated $2.47M and leaving 3,970 shares worth $1.77M. The position accounts for 0.03% of the portfolio, ranked #133.

Howard Capital Management first reported a position in VRTX in Q1 2019 and has held it in 13 quarters since. The position peaked at $4.2M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Howard Capital Management held 3,970 shares of Vertex Pharmaceuticals worth $1.77M as of Q1 2026.
Howard Capital Management sold 5,304 Vertex Pharmaceuticals shares in Q1 2026, an estimated $2.47M.
Vertex Pharmaceuticals made up 0.03% of Howard Capital Management's portfolio in Q1 2026, its #133 holding.
Howard Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 13 quarters since.
Howard Capital Management's Vertex Pharmaceuticals position peaked at $4.2M in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Howard Capital Management's 13F filing for Q1 2026, filed 5 May 2026.